Formulation development and characterization of a Marburg self-amplifying mRNA-lipid nanoparticle vaccine with toll-like receptor-7 agonists

ECI Vaccine IX 2024 -- Self-amplifying RNA (sa mRNA) formulated in lipid nanoparticles (LNPs) is a novel vaccine modality and is being used to develop a Marburg Virus vaccine comprising the Glycoprotein (MARV) sa mRNA. Imidazoquinoline TLR-7 agonists have been encapsulated with the MARV sa mRNA-LNP with the aim of testing for adjuvancy in vivo. A design of experiment (DoE) approach was used to optimize the encapsulation of resiquimod and telratolimod (alkylated imidazoquinoline) to develop a lead candidate and to met the anticipated critical quality attributes (CQAs).